(Total Views: 551)
Posted On: 06/07/2021 1:45:30 PM
Post# of 153903
Quote:
when the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients and there remains some uncertainty about the drug's clinical benefit.
In this case the surrogate endpoint is a reduction in plaque. There is not a proven correlation between plaque reduction and positive effect on Alzheimer's disease.
Quote:
In surprising twist, some Alzheimer's plaques may be protective, not destructive
https://www.sciencedaily.com/releases/2021/04...114143.htm
(8)
(1)
